Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

June 9th 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

May 13th 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

May 6th 2024

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.

Multidisciplinary Collaboration Plays Key Role in Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL

May 2nd 2024

Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology

April 24th 2024

Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024

Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.

Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

April 22nd 2024

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups

April 15th 2024

Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Zamarin Shares Updates and Ongoing Research Endeavors in Gynecologic Oncology

March 29th 2024

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

Efstathiou on the Status of Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

March 27th 2024

Jason Efstathiou, MD, discusses the status of bladder preservation therapy for muscle-invasive bladder cancer.

Shifting Therapies to Earlier Settings Could Bolster Treatment Options in mHSPC and Oligometastatic Prostate Cancer

March 26th 2024

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

Looking Beyond PSA Is Key to Understanding Nuances of Prostate Cancer Treatment

March 25th 2024

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Taplin Tackles Equitable Treatment in Prostate Cancer

March 24th 2024

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.